{'fraction_non_alphanumeric': 0.023517382413087935, 'fraction_numerical': 0.0081799591002045, 'mean_word_length': 5.235668789808917, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Evolving Role of Automation in CAR-T Cell Commercialization

Andrew Kaiser joined Miltenyi Biotec’s R&D in 2012, where he heads a team that focuses on developing tools and technologies for clinical applications of adoptive cell therapy and more specifically the automation of gene-modified T cell manufacturing. During his PhD, he focused on translational research of dendritic cell maturation for vaccines at IDM Pharma and at the Cochin Institute in Paris, France. As post-doc, he aimed to further cancer immunotherapy using gene-modified T cells at the Surgery Branch of the NCL, Bethesda, USA and later at the Netherlands Cancer Institute in Amsterdam. Dr. Kaiser is also the scientific coordinator of a Horizon 2020 European consortium called CARAT, that aims to integrate innovative cell manufacturing tools and enabling technologies into a new comprehensive platform that will facilitate the safe, automated, and cost-effective manufacture of gene-engineered T-cells.